Category Archives: J Am Acad Dermatol

Related Articles

Reply to: “Pruritus with pemphigoid autoantibodies is the tip of an iceberg”.

J Am Acad Dermatol. 2019 11;81(5):e153-e154

Authors: Lamberts A, Meijer JM, Diercks GFH, Pas HH, Horváth B

PMID: 31369772 [PubMed – indexed for MEDLINE]

Continue reading →

Pain management in patients with hidradenitis suppurativa.

J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S47-51

Authors: Horváth B, Janse IC, Sibbald GR

Abstract
Hidradenitis suppurativa (HS) is a chronic, relapsing, and painful inflammatory disease. HS patients’ quality of life is severely impaired, and this impairment correlates strongly with their pain. Pain in HS can be acute or chronic and has both inflammatory and noninflammatory origins. The purpose of this review is to provide a summary of the existing literature regarding pain management in patients with HS. While there are no formal studies investigating pain management in HS, existing recommendations are based on general pain guidelines and expert opinion. Documentation of pain requires an assessment of the severity and timing of the pain. Although anti-inflammatory drugs and surgery for HS can alleviate pain, adjunctive pain medications are typically necessary. Topical analgesics, oral acetaminophen, and oral nonsteroidal anti-inflammatory drugs are considered first-line agents for the treatment of pain in patients with HS. If pain management is ineffective with those agents, oral opiates can be considered. In addition, anticonvulsants and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors possess neuropathic pain-relieving properties that offer not only control of HS-associated pain but beneficial effects on itch and depression. There is clearly a need for additional studies on pain management in patients with HS.

PMID: 26470616 [PubMed – in process]

Continue reading →

Related Articles

Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts.

J Am Acad Dermatol. 2015 Jan;72(1):168-74

Authors: Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, Amagai M, Bauer J, Beissert S, Borradori L, Culton D, Fairley JA, Fivenson D, Jonkman MF, Marinkovich MP, Woodley D, Zone J, Aoki V, Bernard P, Bruckner-Tuderman L, Cianchini G, Venning V, Diaz L, Eming R, Grando SA, Hall RP, Hashimoto T, Herrero-González JE, Hertl M, Joly P, Karpati S, Kim J, Chan Kim S, Korman NJ, Kowalewski C, Lee SE, Rubenstein DR, Sprecher E, Yancey K, Zambruno G, Zillikens D, Doan S, Daniel BS, Werth VP

Abstract
Mucous membrane pemphigoid encompasses a group of autoimmune bullous diseases with a similar phenotype characterized by subepithelial blisters, erosions, and scarring of mucous membranes, skin, or both. Although knowledge about autoimmune bullous disease is increasing, there is often a lack of clear definitions of disease, outcome measures, and therapeutic end points. With clearer definitions and outcome measures, it is possible to directly compare the results and data from various studies using meta-analyses. This consensus statement provides accurate and reproducible definitions for disease extent, activity, outcome measures, end points, and therapeutic response for mucous membrane pemphigoid and proposes a disease extent score, the Mucous Membrane Pemphigoid Disease Area Index.

PMID: 25443626 [PubMed – indexed for MEDLINE]

Continue reading →

Related Articles
Comments on: DRESS syndrome.
J Am Acad Dermatol. 2014 Nov;71(5):1000-1000.e2
Authors: Kardaun SH, Mockenhaupt M, Roujeau JC
PMID: 25437959 [PubMed – in process]

Continue reading →

Related Articles
Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.
J Am Acad Dermatol. 2014 Jun;70(6):1103-26
Authors: Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW… Continue reading →

Related Articles

Successful therapeutic transplantation of revertant skin in epidermolysis bullosa.

J Am Acad Dermatol. 2014 Jan;70(1):98-101

Authors: Gostyński A, Pasmooij AM, Jonkman MF

Abstract
BACKGROUND: Epidermolysis bullosa (EB) is a group of genetic blistering diseases. Despite many efforts, treatment for EB remains symptomatic. Revertant mosaicism, coexistence of cells carrying disease-causing mutations with cells in which the inherited mutation is genetically corrected by a spontaneous genetic event (revertant cells) in 1 individual, can be found in EB. The naturally corrected revertant keratinocytes provide an opportunity for autologous cell therapy.
OBJECTIVE: We sought to locally treat EB by transplantation of revertant skin.
METHODS: Persistent ulcers in a patient with non-Herlitz junctional EB caused by mutations in the LAMB3 gene were treated by transplantation of split-thickness biopsy specimens from one of his revertant patches.
RESULTS: All transplanted biopsy specimens were accepted and complete re-epithelialization occurred within 14 days. During 18 months of follow-up, the patient never experienced blisters or wounds in the grafted area, nor in the healed donor site. Immunofluorescence and DNA sequencing showed that acceptor sites healed with transplanted revertant keratinocytes.
LIMITATIONS: Punch grafting allows only limited expansion of revertant skin.
CONCLUSIONS: We demonstrate that phenotypical and genotypical correction of skin in patients with revertant mosaicism by expansion of revertant skin might be a promising therapeutic option for cutaneous manifestations of EB.

PMID: 24176523 [PubMed – indexed for MEDLINE]

Continue reading →

Related Articles
Punch grafting of chronic ulcers in patients with laminin-332-deficient, non-Herlitz junctional epidermolysis bullosa.
J Am Acad Dermatol. 2013 Jan;68(1):93-7, 97.e1-2
Authors: Yuen WY, Huizinga J, Jonkman MF
… Continue reading →

Related Articles
Topical sirolimus for oral pemphigus vulgaris: 3 unresponsive cases.
J Am Acad Dermatol. 2012 Nov;67(5):e228-9
Authors: Poot AM, Jonkman MF
PMID: 23062929 [PubMed – in process]

Continue reading →

Related Articles
Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.
J Am Acad Dermatol. 2006 Aug;55(2 Suppl):S21-3
Authors: Kardaun SH, de Monchy… Continue reading →

Related Articles
Risk of squamous cell carcinoma in junctional epidermolysis bullosa, non-Herlitz type: report of 7 cases and a review of the literature.
J Am Acad Dermatol. 2011 Oct;65(4):780-9
Authors: Yuen WY, Jonkman MF
… Continue reading →